Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to a 13-month high extending beyond a buy zone.

The post Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps appeared first on Investor's Business Daily.